Cellipont Bioservices, a cell therapy CDMO, and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated manufacturing platform for advanced cell therapies, partnered to leverage Adva Biotechnology’s ADVA X3 platform in North America. The ADVA X3 is an advanced, fully automated platform for manufacturing cell therapies, that aims to streamline processes and reduce costs.  
 
The ADVA X3 system is designed to simplify and accelerate the manufacturing of CAR-T therapies from manual to fully automated and cGMP in as little as three months. It also makes it accessible to a broader patient population. The combination of Cellipont’s process and manufacturing expertise and purpose-built facility coupled with the ADVA X3 metabolic sensing-based AI-driven automated manufacturing platform allows therapy developers to quickly go from manual processing to fully automated and cGMP. The ADVA X3 system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
 
“We’re proud to partner with Adva Biotechnology and be the first CDMO in North America to offer the ADVA X3® to clients. The ADVA X3’s automation and precision are game changers, enabling us to scale up production and meet the urgent needs of patients,” said Michael O’Mara, COO of Cellipont Bioservices.
 
“The collaboration with Cellipont Bioservices is a pivotal moment for us,” said Dr. Ohad Karnieli, CEO of Adva Biotechnology. “The ADVA X3® embodies our commitment to innovation and patient care, and with Cellipont’s expertise, we’re set to transform the landscape of cell therapies.”